{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Response rates calculated based on the Response Evaluation Criteria in Solid Tumors (RECIST)/RECIST Immunotherapy and Cheson criteria (Phase 2 only). Response rate data will be summarized using proportions with exact 95% confidence intervals, means, standard deviations, and ranges.","groups":[{"description":"Participants receive ipilimumab intratumorally on Day 1\n\nIpilimumab: Given intratumorally","id":"OG000","title":"Ipilimumab 25 mg"},{"description":"Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions\n\nIpilimumab: Given intratumorally\n\nRadiation therapy: Undergo local radiation therapy, 10 Gy x 3 fractions","id":"OG001","title":"Ipilimumab 25 mg and Radiation Therapy"}],"populationDescription":"This was a study phase 2 outcome, and no participants were enrolled in study phase 2.","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Response Rate (Phase 2 Only)","type":"SECONDARY"}